Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone calls and/or email reminder survey.
SECONDARY OBJECTIVES:
I. Evaluate whether there are differences in the length of vaginal canal between the non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and gastrointestinal toxicity.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive no additional reminders.
ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months, 11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Stanford、California、アメリカ、94305
- Stanford University, School of Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
- Patients cannot have previously received pelvic external beam radiation or brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy radiation treatment.
- Patients should have a life expectancy of at least 1 year
- No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status requirements
- No organ and marrow function requirements
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
- No restrictions regarding use of other investigational agents
- No exclusion requirements due to co-morbid disease or intercurrent illness
- No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
- No exclusion criteria relating to concomitant medications
- No exclusion criteria for pregnant or nursing patients from participating in this study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Arm I (no intervention)
Patients receive no additional reminders.
|
|
|
実験的:Arm II (email survey)
Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
|
Receive reminder email survey
Receive reminder email survey
|
|
実験的:Arm III (email surveys and phone calls)
Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
|
Receive reminder email survey
Receive reminder email survey
Receive reminder phone call
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation
時間枠:Up to 25 months after completing radiation
|
The vaginal dilator adherence measurements will analyzed in repeated measures model with treatment as a fixed effect and time as a within subject effect.
The overall mean of vaginal dilator adherence among the 3 groups will also be measured and compared.
The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
|
Up to 25 months after completing radiation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vaginal canal length
時間枠:Up to 25 months after completing radiation
|
The vaginal canal length will be measured using an extra small dilator and it will be calculated in centimeters.
The vaginal canal length measurements will be analyzed in a repeated measures model with treatment as a fixed effect and time as a within subject effect.
The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
|
Up to 25 months after completing radiation
|
|
Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03
時間枠:Up to 30 days after the last dose of study treatment
|
The adverse events will be tabulated by type and grade at each follow up.
The total number of AE's as well as the number of AE's in each category: gynecologic, urinary and gastrointestinal will tabulated.
The test of proportion will be done per category of AE.
Since it is possible that the rates will be low, an exact test will be used to compare the rates.
|
Up to 30 days after the last dose of study treatment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Elizabeth Kidd、Stanford University Hospitals and Clinics
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。